Biotech Stock Climbs on Coronavirus Therapy Update

Lattice Biologics Ltd. (TSXV:LBL), a biotech stock, powered up after announcing plans to evaluate its ARDS treatment related to Coronavirus

Sean Mason | March 13, 2020 | SmallCapPower

Potential treatment for acute respiratory distress syndrome (ARDS) boosted a Canada-listed biotech stock Friday. Here’s some small stocks making big moves on Friday, March 13, 2020 (as of 4 pm EST):

Lattice Biologics Ltd. (TSXV:LBL), a Canada-listed biotech stock, jumped 200% to $0.075 on Friday after announcing that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, which the Company believes has potential for use in the treatment with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).

Win Big With Our Small Cap Picks

 

As well, units of Nexus Real Estate Investment Trust (TSXV:NXR.UN) gained 10% to $1.88 as the real estate investment trust focused on North American industrial, office and retail properties said its 2019 net income increased 9.2% to $42.4 million.

WELL Health Technologies Corp. (TSX:WELL), meanwhile, reported that it is rapidly ramping up efforts on its recently-launched VirtualClinic+ telehealth service due to the anticipated demand for health services generated by the COVID-19 pandemic. WELL Health Technologies stock moved up 3% to $1.39 following the announcement.

See more Small and Micro Cap Market Movers Daily from Sean Mason. Tomorrow’s big stock market winners could be found here today!

Hi, did you know SmallCapPower accepts blog submissions? You can contact me here

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below: